Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Hana Pharm Co., Ltd. is a leading South Korean pharmaceutical company specializing in the development and manufacturing of generic and specialty drugs. The company has a robust portfolio of over 300 products, primarily focused on oncology, cardiology, and infectious diseases, which positions it competitively in both domestic and international markets.
Hana Pharm generates revenue through the sale of generic and specialty pharmaceuticals, leveraging its strong R&D capabilities to develop cost-effective alternatives to branded drugs. The company benefits from pricing power in the generic segment due to its established relationships with healthcare providers and distributors.
Regulatory approvals for new generic drugs
Market share gains in oncology and cardiology segments
Changes in healthcare policies affecting drug pricing
Currency fluctuations impacting international sales
Regulatory changes impacting drug approval processes
Technological disruption in drug development
Intensifying competition from domestic and international generic manufacturers
Potential entry of large pharmaceutical companies into the generic market
High capital expenditures impacting free cash flow
Potential liquidity issues due to negative free cash flow
moderate - As a healthcare company, Hana Pharm's performance is somewhat insulated from economic downturns, but demand for its products can be influenced by overall consumer spending and healthcare budgets.
Interest rates affect Hana Pharm primarily through financing costs for R&D and capital expenditures. Higher rates could compress margins if borrowing costs increase significantly.
minimal - The company's low debt-to-equity ratio of 0.21 indicates a strong balance sheet with limited reliance on external financing.
value - The low price-to-earnings and price-to-book ratios suggest potential for value-oriented investors looking for recovery in earnings.
moderate - The company's historical volatility is in line with the broader pharmaceutical sector, reflecting both operational risks and market conditions.
